{'fraction_non_alphanumeric': 0.02354480052321779, 'fraction_numerical': 0.013080444735120994, 'mean_word_length': 5.144578313253012, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study

The PREDICT study was designed to assess the real-world and long-term health-related quality of life in adults with chronic migraine receiving onabotulinumtoxinA in Canada. 1 There have been several studies published on the long-term ef ﬁ cacy and safety of onabotulinumtoxinA after it was approved for clinical use in chronic migraine patients based on the result from the PREEMPT study. 2 One study was the COMPEL study in which it established signi ﬁ cance with headache days reduction and improvement in disability based on the Headache Impact Test (HIT-6) and Migraine Disability Assessment Questionnaire (MIDAS) over a span of 108 weeks. 3 The REPOSE study demonstrated long-term (24 months) real-world data on effectiveness of onabotulinumtoxinA with sustained reduction in headache days frequency and signi ﬁ cant improvement in quality-of-life measures. 4 However, these studies enrolled non-Canadian populations. The PREDICT study is a multicenter, prospective study with data collected across headache/pain centers in Canada. Appropriate screening was performed with a 4-week baseline period. Treatments were based on the PREEMPT paradigm, 2 155 units of onabotulinumtoxinA administered at 31 ﬁ xed sites with optional additional injections for a total dose of 195 units (follow the pain pattern). The PREDICT study was an observational study; hence, no formal sample size calculations were formed, or no formal hypothesis was tested.